BioRxiv

Applied DNA and EvviVax Announce Peer-Reviewed Publication of Positive Preclinical Data for LinearDNA™ Platform as a Novel Cancer Vaccine Strategy in the Journal of Experimental & Clinical Cancer Research

Retrieved on: 
Monday, June 6, 2022
Research, Other Health, Oncology, Infectious Diseases, Genetics, Fitness & Nutrition, Clinical Trials, Science, Veterinary, Biotechnology, FDA, Health, Other Science, USDA, Company, Paper, Survival, BioRxiv, PETS, CRISPR, Cannabis, COVID-19 testing, PCR, COVID-19, History, Cancer, TCR, Infection, Association, Textile, Journal, Food, Forward-looking statement, CEO, TERT, United States Department of Agriculture, Trial of the century, Securities Exchange Act of 1934, Dog, Securities Act of 1933, Russell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Calendar, Cancer immunotherapy, Vaccine, Annual report, RNA, Lymphoma, Journal of Experimental & Clinical Cancer Research, DNA, SEC, Private Securities Litigation Reform Act, Experiment, Program, Research, LNP, Drug Quality and Security Act, LinkedIn, FDA, EGT, NASDAQ, Twitter, Clinical trial, United States Department of State, Zoonosis, Pharmaceutical industry, Applied DNA Sciences, Veterinary medicine

("EvviVax"), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNAs LinearDNA platform to produce veterinary DNA cancer vaccines.

Key Points: 
  • ("EvviVax"), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNAs LinearDNA platform to produce veterinary DNA cancer vaccines.
  • LinearDNA is Applied DNA's proprietary, large-scale polymerase chain reaction (PCR)-based manufacturing platform that allows for the large-scale, cell-free production of high-fidelity DNA sequences.
  • Applied DNA has exclusively licensed the anti-telomerase reverse transcriptase (TERT) cancer vaccine studied in the paper for its LinearDNA platform for veterinary applications.
  • The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market.

Ultima Genomics Delivers the $100 Genome

Retrieved on: 
Tuesday, May 31, 2022
Cancer Research UK, Whitehead Institute, Health, Software, D1 Capital Partners, Genome, Company, General Atlantic, DNA, Stanford University, Harvard University, Multimedia, Biology, Baylor University, MIT, Biomedical Research, Architecture, Research, RNA-Seq, Personalized medicine, Center, Broad, Genomics, Methylation, Neoplasm, Founders Fund, Broad Institute, Machine learning, Adoption, Ultima, Khosla Ventures, Baylor College of Medicine, BioRxiv, Diagnosis, German Resource Center for Genome Research, Antibiotics, Vaccine, Speed of light

NEWARK, Calif., May 31, 2022 /PRNewswire/ -- Today Ultima Genomics emerged from stealth mode with a new high-throughput, low-cost sequencing platform that delivers the $100 genome.  Ultima's goal is to unleash a new era in genomics-driven research and healthcare, and it has secured approximately $600 million in backing from leading investors who share this vision.

Key Points: 
  • NEWARK, Calif., May 31, 2022 /PRNewswire/ -- Today Ultima Genomics emerged from stealth mode with a new high-throughput, low-cost sequencing platform that delivers the $100 genome.
  • "Ultima Genomics' architecture will revolutionize sequencing and take what we can do to a whole new level," said Michael Snyder, Director of the Center for Genomics and Personalized Medicine at Stanford University.
  • "We have seen the quality of Ultima Genomics sequencing in millions of single cells, and now are initiating even larger experiments that weren't previously feasible."
  • Ultima Genomics is unleashing the power of genomics at scale.

Elicio Therapeutics Announces Publication of Preclinical Data Showing AMP-Peptide Vaccine in Combination with TCR-T Cell Therapy Enhances Anti-Tumor Function and Eradicates Solid Tumors

Retrieved on: 
Monday, May 23, 2022
Cancer, Darrell Irvin, NY-ESO-1, Engineering, Immunotherapy, Research, Koch Institute, KRAS, Infection, Vaccine, Vaccination, Therapy, MIT, DRS, Amplifier, Biomedical engineering, COVID-19, AMP, Immunology, Koch Institute for Integrative Cancer Research, FDA, TCR, Biomedicine, Peptide, Forward-looking statement, Plague, Compliance, Massachusetts Institute of Technology, BioRxiv, Immune system, E7, Lymph, Laboratory, GLOBE, Pharmaceutical industry, Amphiphile, Elicio Berriz

Dylan Drakes and Peter DeMuth, with Elicio colleagues, were published in the preprint server, bioRxiv, and can be found here .

Key Points: 
  • Dylan Drakes and Peter DeMuth, with Elicio colleagues, were published in the preprint server, bioRxiv, and can be found here .
  • T cell receptor (TCR)-modified T cell therapies have historically shown promise but challenges to clinical efficacy against solid tumors persist.
  • Often, suboptimal clinical performance can be attributed to insufficient in vivo persistence of current treatments and tumor antigen escape.
  • In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability.

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Retrieved on: 
Thursday, May 19, 2022
Severe acute respiratory syndrome coronavirus 2, Serum, Risk, Duke University, Family, Immunoglobulin G, Infection, Centers for Disease Control and Prevention, Vaxart, Vaccine, NASDAQ, Vaccination, Antibody, Coronavirus, Norovirus, Saliva, Science Translational Medicine, Clinical trial, COVID-19, Research, Patent, FDA, Report, SAN, Immunoglobulin A, S, Refrigeration, Immunity, Compliance, Middle East respiratory syndrome–related coronavirus, Safety, TLR3, Tablet, Animal, Face, Respiratory syncytial virus, Quality control, BioRxiv, RSV, Injury, (S)-coclaurine-N-methyltransferase, N, HPV, GLOBE, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Science Translational Medicine has published the results of a Duke University-led preclinical hamster transmission study that found that Vaxart’s (NASDAQ: VXRT) S-only oral COVID-19 vaccine candidate inhibited the transmission of SARS-CoV-2. The report also described updated results from Vaxart’s Phase I clinical trial that suggest Vaxart’s other vaccine candidate, the one targeting both the S and N proteins, could be effective against a range of diverse coronaviruses.

Key Points: 
  • The study authors concluded that Vaxarts S-only construct reduced disease and decreased airborne transmission in a hamster model.
  • The S-only data from the hamster transmission preclinical study was initially reported last October in the non-peer reviewed journal bioRxiv .
  • The new Science Translational Medicine publication includes additional detail regarding IgA antibody responses in human subjects.
  • Vaxart has moved to Phase II clinical trials with the S-only vaccine candidate and expects to report those results later this year.

Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Retrieved on: 
Thursday, May 19, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Severe acute respiratory syndrome coronavirus 2, Contract, DHA, Disease, ACE2, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, U.S. Securities and Exchange Commission, Nasdaq, Doctor of Philosophy, Patient, Infection, Phagocytosis, Goal, DOD, Antibody, Viral load, Nature, Clinical trial, Defense, COVID-19, Research, FDA, Defense Health Agency, Time-invariant system, U.S. Department of Defense Strategy for Operating in Cyberspace, Forward-looking statement, Safety, Joint Program Executive Office Chemical and Biological Defense, Therapy, BioRxiv, LinkedIn, Epitope, Immune system, Twitter, SEC, Radiation, Annual report, CEO, Vaccine, Pharmaceutical industry, Chemical substance, Omicron, Immunome

Additional in vitro testing of a SARS-CoV-2 pseudovirus also showed that IMM20253, one of the antibodies in Immunomes cocktail, successfully neutralized the Omicron subvariant (BA.2).

Key Points: 
  • Additional in vitro testing of a SARS-CoV-2 pseudovirus also showed that IMM20253, one of the antibodies in Immunomes cocktail, successfully neutralized the Omicron subvariant (BA.2).
  • When tested in hamster models, IMM-BCP-01 retained full coverage against the Omicron variant.
  • Specifically, the data suggest strong activity of two antibodies in the cocktail, IMM20253 and IMM20184, which target distinct, non-overlapping epitopes of SARS-CoV-2, against the Omicron variant.
  • Dr. Sarma continued, Notably, these data indicate that in vitro viral neutralization assays may not fully predict the in vivo activity of Immunomes cocktail.

Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022
Infection, Antibody, COVID-19, Respiratory syncytial virus, Home After Three Months Away, Report, Volunteering, Immunoglobulin A, NASDAQ, GLOBE, BioRxiv, RSV, Tablet, Safety, Research, Refrigeration, Coronavirus, Clinical trial, Risk, FDA, Norovirus, Injury, Compliance, Patent, Alpha, Ageing, Severe acute respiratory syndrome coronavirus 2, Beta, Vaccine, TLR3, Sale, HPV, Quality control, SEC, Serum, Vaccination, Technology, Gamma, Nasal mucosa, Pharmaceutical industry, Video game, Vaxart

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) issued its business update today for the first quarter of 2022, reporting continued progress on its oral vaccine candidates.

Key Points: 
  • Results from Vaxarts Phase IB trial of its norovirus vaccine candidate in elderly subjects are expected in the second quarter of 2022.
  • The Companyreported a net loss of$25.1 millionfor the first quarter of 2022, compared to$16.0 million for the first quarter of 2021.
  • Research and development expenses were$18.2 millionfor the first quarter of 2022, compared to$10.1 million for the first quarter of 2021.
  • General and administrative expenses were$6.7 millionfor the first quarter of 2022, compared to$5.9 million the first quarter of 2021.

Clover’s Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of Concern

Retrieved on: 
Thursday, May 5, 2022
COVID-19, Forward-looking statement, Omicron, EMA, Mouse, GLOBE, CpG, Development, BioRxiv, WHO, 1018, Aluminium, Bivalent, SCB-2019, Volatile organic compound, Manuscript, Severe acute respiratory syndrome coronavirus 2, Vaccine, NMPA, Organic compound, Vaccination, Trimer, VOC, Clover

SHANGHAI, China, May 05, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced new promising data from a preclinical study on Clover’s bivalent vaccine candidate, which combines the trimeric spike antigens from the original SARS-CoV-2 strain and the Omicron variant. The bivalent vaccine candidate elicited broad neutralization against all Variants of Concern (VoC), including Omicron, in both primary vaccination and booster settings in a preclinical study. The manuscript “Cross-Protection to VOCs by Bivalent S-Trimer COVID19 Vaccine” is available for pre-print on bioRxiv and will be submitted for peer-review publication in a scientific journal.

Key Points: 
  • The bivalent vaccine candidate elicited broad neutralization against all Variants of Concern (VoC), including Omicron, in both primary vaccination and booster settings in a preclinical study.
  • Thus, we believe there is a potential licensure pathway for the bivalent candidate based on clinical immuno-bridging to SCB-2019 (CpG 1018/Alum).
  • In the pre-clinical study, the bivalent COVID-19 vaccine candidate was comprised of the trimeric spike proteins from the original strain (SCB-2019) and the Omicron variant (SCB-2022B).
  • Importantly, compared to the monovalent Omicron variant vaccine (SCB-2022B) alone, the bivalent COVID-19 vaccine demonstrated higher levels of neutralization against most of the variants tested and comparable levels against Omicron.

Promising New Universal Coronavirus Vaccine Candidate Discovered

Retrieved on: 
Wednesday, May 4, 2022
Possibility, Cold Spring Harbor Laboratory, Human, Lists of countries and territories, Altmetric, Preprint, Immune system, Machine learning, Organic acid, The New England Journal of Medicine, Patient, BioRxiv, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Vaccine, Animal

INTERLOCHEN, Mich., May 4, 2022 /PRNewswire/ -- Today, Cold Spring Harbor Laboratory published a preprint in BioRxiv of a study conducted by Eric Luellen which identifies a new promising universal coronavirus vaccine candidate. It attenuates 361 out of 365 coronaviruses tested (99%), including all known SARS-CoV-2 variants. The author released the formula to be freely accessible to help poorer countries have greater access to a vaccine to combat the pandemic.

Key Points: 
  • INTERLOCHEN, Mich., May 4, 2022 /PRNewswire/ -- Today, Cold Spring Harbor Laboratory published a preprint in BioRxiv of a study conducted by Eric Luellen which identifies a new promising universal coronavirus vaccine candidate.
  • The author released the formula to be freely accessible to help poorer countries have greater access to a vaccine to combat the pandemic.
  • "Until a universal vaccine is widely available, new variants of this coronavirus and many like it will threaten humankind," said Luellen.
  • The vaccine candidate formula by transforming viral genomic sequence data and analyzing it computationally using machine learning.

Ring Therapeutics Announces Publication Highlighting In Vivo Delivery and Tropism of the First Synthesized Human Anelloviruses Using a Recombinant Genome

Retrieved on: 
Monday, May 2, 2022
Twitter, Flagship Pioneering, GLOBE, BioRxiv, Engineering, Re Recher's Will Trusts, MD, Tissue, Tropism, Plasmid, MBA, Ring, AAV2, Biology, Therapy, Vaccine

The study also showcases the tissue-specific delivery of these synthesized anelloviruses in vivo, a significant milestone in Rings efforts for engineering the next generation of redosable viral vectors through its AnellogyTM platform.

Key Points: 
  • The study also showcases the tissue-specific delivery of these synthesized anelloviruses in vivo, a significant milestone in Rings efforts for engineering the next generation of redosable viral vectors through its AnellogyTM platform.
  • In the study, Ring researchers successfully developed an in vitro system to effectively produce anelloviruses and recapitulated tissue-specific delivery in vivo.
  • Using a human cell line transfected with plasmids encoding an anellovirus genome, two distinct anelloviruses were produced in vitro, validated by viral gene expression, replication and imaging.
  • Ring Therapeutics is revolutionizing the gene therapy and nucleic acid medicine space by harnessing the most abundant and diverse member of the human commensal virome, anelloviruses.

TFF Pharmaceuticals Announces Multiple Presentations Highlighting Broad Applicability of its Thin Film Freezing Technology at Respiratory Drug Delivery Meeting (RDD)

Retrieved on: 
Monday, May 2, 2022
Drug development, Pulmonary fibrosis, Inhalation, Safety, Exhibition, Interface, Powder, Poster, Annual report, Artificial intelligence, Skin, Young Scientist and Technology Exhibition, University of Florida College of Pharmacy, Antibody, Solubility, Technology, CEO, Risk, Fight Against Coercive Tactics Network, NASDAQ, Water, BioRxiv, Company, Voriconazole, College, Lung, FDA, Government, Research, Freezing, Podium, University of Texas at Austin, RDD, Degenerative disease, Vaccine, Cros, Protein, COVID-19, Escherichia coli, Absorption, GLOBE, University, TFF, Nose, Medical device, Pharmaceutical industry, Lactoferrin

FORT WORTH, Texas, May 02, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced substantial new data to be presented on its technology platform at the Respiratory Drug Delivery (RDD) Meeting, which is taking place between May 1-5, 2022 in Orlando, Florida.

Key Points: 
  • (Bill) Williams III, Ph.D., co-inventor of Thin Film Freezing technology and special advisor to TFF Pharmaceuticals, will deliver a platform presentation with data on stabilizing and delivering antivirals, antibodies and vaccines using Thin Film Freezing technology in the fight against COVID-19 and other serious viral infections.
  • Additionally, Dr. Williams and his colleagues will present five posters highlighting the broad applicability of Thin Film Freezing to improve drug development of biologics and small molecules for respiratory diseases, including pulmonary fibrosis and COVID-19.
  • The findings from Dr. Williams lab also highlight how Thin Film Freezing can be used to facilitate delivery of other treatment modalities, such as gene therapy.
  • "We are excited to share these data showcasing the incredible versatility of the Thin Film Freezing platform at the RDD conference," said Glenn Mattes, CEO of TFF Pharmaceuticals.